Product
Coformulated CIC Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of AgeStatus: Not yet recruiting, Estimated PCD: 2024-11-16